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One of the fundamental questions regarding the pathogenesis of Alzheimer’s disease (AD) is how the monomeric, nontoxic amyloid β-protein
(Aβ) is converted to its toxic assemblies in the brain. A unique Aβ species was identified previously in an AD brain, which is characterized by its
binding to the GM1 ganglioside (GM1). On the basis of the molecular characteristics of this GM1-bound Aβ (GAβ), it was hypothesized that Aβ
adopts an altered conformation through its binding to GM1, and GAβ acts as a seed for Aβ fibrillogenesis in an AD brain. To date, various in vitro
and in vivo studies of GAβ have been performed, and their results support the hypothesis. Using a novel monoclonal antibody specific to GAβ, it
was confirmed that GAβ is endogenously generated in the brain. Regarding the role of gangliosides in the facilitation of Aβ assembly, it has
recently been reported that region-specific deposition of hereditary variant-type Aβs is determined by local gangliosides in the brain. Furthermore,
it is likely that risk factors for AD, including aging and the expression of apolipoprotein E4, alter GM1 distribution on the neuronal surface,
leading to GAβ generation.
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An invariable and fundamental process in the pathogenesis
of Alzheimer’s disease (AD) is the assembly and deposition of
the amyloid β-protein (Aβ). Aβ naturally assembles at high⁎ Tel.: +81 562 44 5651x5301; fax: +81 562 44 6594.
E-mail address: katuhiko@nils.go.jp.
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.01.018micromolarity concentrations in vitro. However, the concentra-
tion is very low (on the low nanomolarity order) in biological
fluids, including the cerebrospinal fluid [1–3]. In the case of
familial AD, the expression of responsible genes likely
accelerates Aβ assembly owing to an enhanced Aβ generation
[4]; however, no evidence has yet been provided suggesting that
the level of Aβ generation increases in sporadic AD, the major
form of the disease. Thus, it remains to be determined how Aβ
1944 K. Yanagisawa / Biochimica et Biophysica Acta 1768 (2007) 1943–1951starts to assemble in vivo in an age-dependent manner and in a
region-specific manner.
Several mutations within the Aβ sequence are responsible for
familial AD and hereditary amyloid angiopathy [5–7]. Notably,
some of these mutations facilitate Aβ pathological processes
without enhancing Aβ generation. The Arctic-typemutation even
decreases the Aβ1–42/1–40 ratio in secreted Aβs, an increase in
which is supposed to be one of the critical factors for Aβ
assembly. Furthermore, these mutations also induce Aβ assembly
and deposition that preferentially occur in a specific area in the
brain. For example, theDutch-typemutation (E693Q) inducesAβ
deposition preferentially in the cerebral blood vessel walls,
whereas the Arctic-type mutation (E693G) induces predominant
Aβ deposition in the parenchyma of the cerebral cortex.
This line of evidence indicates that Aβ assembly in the brain
is accelerated not only by the enhancement of Aβ generation, but
also by as yet unclarified local assembly-promoting factors. To
determine how Aβ starts to assemble and deposit in the brain,
cerebral cortices of AD patients and nondemented aged
individuals were previously examined by fractionation and
immunochemical Aβ detection in the obtained fractions. In that
study, a unique Aβ species was identified, which is characterized
by its binding to the GM1 ganglioside (GM1), in a brain showing
the early pathological changes of AD [8]. On the basis of the
molecular characteristics of GAβ, it was hypothesized that
GM1-boundAβ (GAβ) acts as a seed for Aβ assembly in theAD
brain. This chapter will focus on the molecular characteristics of
GM1-bound Aβ (GAβ) and its pathological implications in AD.
2. GAβ in AD brain
GAβ was identified in the membrane fractions prepared
from cerebral cortices of brains that showed the earlyFig. 1. Aβ fibrillogenesis in the presence of GM1. (a) Kinetics of Aβ fibrillogenesis. S
aggregates, were incubated at 50 μM and 37 °C in the presence of GM1-containing
absence of liposomes (open circle). The GM1-containing liposomes were also incubat
obtained by excluding background activity at 0 h. Inset: Semilogarithmic plot of the d
fluorescence intensity as a function of time in the case of Aβ incubatedwith GM1-cont
and correlation coefficient values were obtained (r=0.997). F(t) is described by a dif
fibrils from soluble Aβ in the presence of GM1. Aβ40 solutions incubated at 50 μM
liposomes (upper panel). The liposomes are indicated by asterisks. Bar, 50 nm. (Coppathological changes of AD, including diffuse plaque formation
[8]. GAβ showed unique molecular characteristics as follows.
First, this Aβ species showed a retarded mobility and a smeared
appearance on SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). Second, it was not detected using antibodies specific to
the midportion of Aβ. Notably, these unique molecular
characteristics of this Aβ species completely disappeared
following treatment with methanol prior to SDS-PAGE. This
line of evidence led us to speculate that this Aβ species is bound
to a ganglioside. This possibility was strongly supported by the
observation that this Aβ species was specifically recognized by
the HRP-conjugated cholera toxin (CTX), which is a natural and
specific ligand for GM1, one of the major gangliosides in the
brain. Thus, it was concluded that this novel Aβ species is
GM1-bound. Interestingly, GAβ shows a strong tendency to
form large Aβ assemblies and has altered immunoreactivity. On
the basis of these characteristics, it was hypothesized that Aβ
adopts an altered conformation by binding to GM1 and acts as a
seed for the assembly of soluble Aβ in the AD brain.
Subsequently, several investigators performed in vitro studies
and their results support the hypothesis [9–16]. In particular,
Matsuzaki and his colleagues reported that the binding of Aβ to
GM1 is facilitated in cholesterol-rich environment, and it is
dependent on cholesterol-induced GM1 clustering in host
membranes [15].
3. Facilitation of Aβ assembly in presence of GM1
The seeding activity of GAβ was examined using seed-free
Aβ solutions, which were carefully prepared as previously
reported [17]. Briefly, a synthetic Aβ peptide (Aβ1–40 or
Aβ1–42) was dissolved in 0.02% ammonia solution, and
undissolved peptides, which can act as preexisting seeds, wereolutions of synthetic Aβ (Aβ40 and Aβ42), after removal of undissolved peptide
liposomes (filled circle) or GM1-lacking liposomes (plus), or incubated in the
ed in the absence of Aβ (triangle). Thioflavin T (ThT) fluorescence intensity was
ifference, A−F(t), versus incubation time (0–24 h). F(t) represents the increase in
aining liposomes andA is tentatively determined asF (infinity). Linear regression
ferential equation: F′(t)=B−CF(t). (b) Electron micrographs of formed amyloid
and 37 °C for 24 h with GM1-containing liposomes (lower panel) or without
yright 2004 by the Society for Neuroscience).
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showed no increase in the fluorescence intensity of thioflavin
T (ThT), which specifically recognizes amyloid structures. In
contrast, the addition of GM1-containing liposomes induced a
marked increase in ThT fluorescence intensity [18] (Fig. 1a).
Electron microscopy also revealed that Aβ assembly into
amyloid fibrils in seed-free Aβ solutions specifically occurred
in the presence of GM1-containing liposomes [18] (Fig. 1b).
4. Antibody specific to GAβ
To further characterize the GM1-induced facilitation of Aβ
assembly and the molecular characteristics of GAβ, GAβ-
specific antibodies were generated. To raise monoclonal
antibodies, a membrane fraction from the cerebral cortices of
subjects with abundant diffuse plaques was prepared, and GAβ
was then purified from the membrane fraction by Prepcell
electrophoretic fractionation. The purified GAβ was added to
cultured spleen cells obtained from mice using an in vitro
immunization technique. An IgM monoclonal antibody (4396)
was initially obtained [19], and then an IgG monoclonalFig. 2. Characterization of binding specificity of anti-GAβ antibody. (a) Immunoele
were analyzed by immunoelectron microscopy of 4396C or isotype-matched control I
liposomes; GM1(−), GM1-lacking liposomes. Bar, 50 nm. (b) Quantitative binding
4396C (diamond) or isotype-matched control IgG (filled square) following their mixi
also incubated with 4396C (triangle) or isotype-matched control IgG (X). (c) Dot bl
amounts equal to those contained in blotted liposomes (300 ng and 600 ng of Aβ4
BAN052, HRP-conjugated cholera toxin subunit B (CTX), or isotype-matched cont
using Aβ40 or Aβ42, Aβ40 and Aβ42 in amounts equal to those contained in GAβ40
4396C. (Copyright 2004 by the Society for Neuroscience).antibody (4396C) was generated using the genetic class-switch
technique [18]. The specificity of 4396C binding to GAβ was
confirmed by immunoelectron microscopy, a quantitative
binding assay, and a dot blot analysis of liposomes carrying
GAβ on their surfaces [18] (Fig. 2a–c). Notably, 4396C did not
react with the free form of Aβ or GM1. It was examined
whether GAβ acts as a seed using a novel antibody. In a kinetic
study of fibril formation from soluble Aβ, the fluorescence
intensity of ThT, which specifically recognizes amyloid
structures, significantly decreased in the presence of 4396C in
a dose-dependent manner [18] (Fig. 3). On the basis of these
results, it was concluded that soluble Aβ binds to GM1, leading
to the generation of GAβ, and then, this generated GAβ
accelerates Aβ fibrillogenesis from soluble Aβ by acting as a
seed.
5. Evidence of GAβ generation in brain
It was attempted to confirm GAβ generation in the brain
using an antibody specific to GAβ. No immunoreactivity
with 4396C was found in sections of AD brains fixed inctron micrographs of liposomes. GM1-containing and GM1-lacking liposomes
gG staining following incubation with soluble Aβ40. GM1(+), GM1-containing
assay of 4396C to liposomes. GM1-containing liposomes were incubated with
ng with soluble Aβ40 at indicated concentrations. GM1-lacking liposomes were
ot analysis. Left panel: liposomes carrying GAβ (GAβ40), Aβ40, and GM1 in
0; 2 μg and 4 μg of GM1), were blotted. The blots were reacted with 4396C,
rol IgG. Right panel: liposomes carrying GAβ (GAβ40 and GAβ42), prepared
and GAβ42 (600 ng of each peptide), were blotted. The blots were reacted with
Fig. 3. Suppression of amyloid fibril formation from soluble Aβ40 by 4396C. Left panel: soluble Aβ40 was incubated with GM1-containing liposomes in the absence
(filled square) or presence of an antibody (4396C or 4G8). The molar ratios of 4396C to soluble Aβ40 were 0.3:50 (triangle), 1.3:50 (circle) and 4:50 (open square),
and that of 4G8 to Aβ40 was 4:50 (diamond). Right panel: soluble Aβ40 was incubated with preformed Aβ40 fibrils in the absence of an antibody (filled square) or in
the presence of 4396C. The molar ratios of 4396C to soluble Aβ40 were 0.3:50 (triangle), 1.3:50 (circle) and 4:50 (open square). (Copyright 2004 by the Society for
Neuroscience).
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immunoreactivity; however, fixation with Kryofix, which
eliminates the possibility of obtaining false-negative results
that can occur in the case of fixation using formalin, made it
possible to obtain intraneuronal staining with 4396C in the
sections [18] (Fig. 4). To confirm the immunohistochemical
detection of GAβ, fresh brain samples from nonhuman
primates, which naturally develop Aβ deposition after age
25, were examined. The cerebral cortices of seven animals of
different ages were examined. In the sections obtained from
the aged animals (ages 30 and 36), a number of neurons were
strongly immunostained by 4396C showing a granular pattern
[18] (Fig. 5a). Double immunostaining of the sections of the
aged animal revealed the colocalization of intraneuronal
staining by 4396C with that of Aβ or GM1 [18] (Fig. 5b).
Furthermore, GAβ immunoreacted with 4396C only in
samples from the cerebral cortex of the aged animal [18]
(Fig. 5c). These results indicate that GAβ is generated in the
brain.Fig. 4. Immunohistochemistry of GAβ in sections of AD brains. Immunostain-
ing of serial sections of the cerebral cortex of an AD brain fixed in Kryofix and
pretreated with SDS. Neurons (arrowheads) were immunostained by 4396C but
not by 4G8, whereas plaques (arrows) were immunostained by 4G8 but not by
4396C. The asterisks indicate the same blood vessel in the serial sections. Bar,
50 μm. (Copyright 2004 by the Society for Neuroscience).6. GM1 accumulation induced by AD risk factors: putative
alteration of GM1 metabolism in AD
The next issue that should be addressed is how GAβ is
generated in the brain. Aβ is physiologically secreted into the
extraneuronal space and GM1 is expressed on neuronal
surfaces. However, GAβ has not been detected in brains
showing no Aβ deposition [8]. Matsuzaki and his colleagues
previously attempted to elucidate the molecular mechanism
underlying the binding of Aβ to GM1 using liposomes with
various compositions of lipids. They found that the binding of
Aβ to GM1 is accelerated in cholesterol-rich environments
and that this is due to the formation of GM1 clusters,
suggesting that the lipid composition of host membranes is a
critical factor for the facilitation of GAβ generation [15]. It
remains to be clarified whether the local contents of
cholesterol and GM1 in neuronal membranes are altered
under certain biological conditions, including aging and the
expression of apolipoprotein E (apoE), which are strong risk
factors for AD development. In this regard, a previous study
showed that the asymmetric distribution of cholesterol
throughout the lipid bilayers of synaptic plasma membranes
(SPMs) changes with age, resulting in an approximately
twofold increase in cholesterol content in the exofacial leaflet
of SPMs prepared from old mice compared with that from
young mice [20]. On the basis of this finding, cholesterol
distribution in the SPM of human apoE knock-in mice was
analyzed, and it was found that apoE4 knock-in mice showed
an approximately twofold increase in cholesterol content in
the exofacial leaflet compared with apoE3 knock-in mice and
wild-type mice. Thus, it was investigated whether GM1
content in neuronal membranes can be altered under these
conditions. Analysis of brains of apoE3 or apoE4 knock-in
mice at three different ages (2 months, 1 year, and 2 years)
revealed that GM1 content in detergent-resistant membrane
microdomains (DRMs) obtained from synaptosomes increased
with age, and that this increase was more marked in the
Fig. 5. Detection of GAβ in sections of nonhuman primate brains. (a) Immunostaining by 4396C of sections of the cerebral cortices of nonhuman primate brains, which
were fixed in paraformaldehyde, from animals of different ages. Bar, 50 μm. Inset: higher magnification. Bar, 20 μm. (b) Double immunostaining of sections of the
cerebral cortex of a 36-year-old primate brain, which was fixed in paraformaldehyde, following the blocking of autofluorescence by pretreatment with Sudan Black B.
Immunostaining by 4396C colocalizing with that by BAN052 or CTX is shown in the merged image. Bar, 25 μm. (c) Immunoprecipitation of GAβ by 4396C from
cerebral cortices of primates of different ages. Immunoprecipitates were blotted and reacted with BAN052 or HRP-conjugated cholera toxin subunit B (CTX).
(Copyright 2004 by the Society for Neuroscience).
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mouse brains [21] (Fig. 6). Interestingly, the DRMs, which
showed an age-dependent increase in GM1 content, were
apparently unique microdomains distinct from lipid rafts.
Presently, it remains to be clarified how GM1 is accumulated
in SPMs in an age-dependent manner and an apoE4-expression-dependent manner; however, another intriguing
issue is whether an increase in GM1 content in such
microdomains is sufficient to induce fibrillogenesis from
soluble Aβ. To clarify this issue, soluble Aβ was incubated in
the presence of synaptosomes obtained from aged apoE4
knock-in mouse brains. As shown in Fig. 7, the assembly of
Fig. 6. GM1 levels in the DRM fractions isolated from brain synaptosomes. DRM fractions were prepared from three different age groups of apoE3- and apoE4-knock-
in mice. Each lane contains 0.1 μg protein of the DRM fraction isolated from synaptosomes prepared from five brains combined. The blots were reacted with CTX-
HRP. The intensities of the bands relative to those for 8 weeks old mice are indicated. Each column represents the average value±S.D. of three values **p<0.0001,
*p<0.001 (One-way ANOVA combined with Sheffe's test). (From Yamamoto et al., FEBS Lett 569: 135–139, 2004).
1948 K. Yanagisawa / Biochimica et Biophysica Acta 1768 (2007) 1943–1951soluble Aβ into amyloid fibrils was significantly accelerated
in the presence of such synaptosomes [21]. This finding
suggests that a change in the lipid composition in neuronal
membranes, particularly in DRMs, underlie the facilitation of
Aβ assembly and deposition through GAβ formation. ThisFig. 7. Acceleration of Aβ assembly in the presence of synaptosomes prepared fro
different age groups of apoE4-knock-in mice. Aβ solutions were incubated at 50 μM
of precipitates (ppt) and supernatants (sup) of the incubation mixtures. The precipita
solubilization of assembled Aβ in formic acid. Aβ in the supernatant was subjected t
blots were reacted with 4G8. The intensities of the bands relative to those for 8 weeks
**p<0.0001, *p<0.05 (One-way ANOVA combined with Sheffe's test). (From Yamhas recently been supported by the following studies. First,
Fredman and her colleagues found that the GM1 content is
high in membrane microdomains isolated from the frontal
cortex, but not in those isolated from the temporal cortex,
reflecting the earlier and later stages of AD development,m aged apoE4-knock-in mouse brains. Synaptosomes were isolated from three
and 37 °C for 24 h in the presence or absence of the synaptosomes. Western blots
tes from 100 μl of incubation mixture were subjected to SDS-PAGE following
o SDS-PAGE following dilution with 200-fold volume of incubation buffer. The
old mice are indicated. Each column represents the average±S.D. of three values.
amoto et al., FEBS Lett 569: 135–139, 2004).
1949K. Yanagisawa / Biochimica et Biophysica Acta 1768 (2007) 1943–1951respectively [22]. Second, Cole and his colleagues reported
that GM1 level increases in amyloid-positive neuritic
terminals obtained from the AD cortex [23].
7. Region-specific Aβ assembly and deposition induced by
local gangliosides
Several mutations within the Aβ sequence are responsible
for familial AD and hereditary amyloid angiopathy. Notably,
these mutations induce Aβ assembly and deposition that
preferentially occur in a specific area in the brain. ForFig. 8. Selective expression of GM3 and GD3 by cerebrovascular smooth muscle (H
cells were separated by two-dimensional TLC. STD: standard. Arrows 1, 2, 3, 4, 5, 6
(b) Immunocytochemistry of cultured endothelial cells and astrocytes and coculture of
against CD31 (H-300) and GFAP (Z0334), respectively. The cocultured endothelial
were also double-immunostained with an antibody against GD3 (R24). The cocult
pretreatment for permeabilization. Arrows (1) and (2) indicate endothelial cells and as
(From Yamamoto et al., FEBS Lett 579: 2185–2190, 2005).example, the Dutch-, Italian- and Iowa-type mutations induce
Aβ deposition preferentially in cerebral blood vessel walls
[5,24–26], whereas the Arctic-type mutation (E693G)
induces predominant Aβ deposition in the parenchyma of
the cerebral cortex [7]. The Flemish-type mutation induces
Aβ deposition that starts from the outer surface of cerebral
blood vessels [27]. This region-specific deposition led us to
hypothesize that the assembly and deposition of these
hereditary variant-type Aβs are dependent on the presence
of local factors, for example, the presence of region-specific
gangliosides. To examine this possibility, lysates of humanCSM) cells and astrocytes, respectively. (a) Gangliosides extracted from HCSM
and 7 indicate GM3, GM2, GM1, GD1a, GD1b, GT1b and GQ1b, respectively.
these cells. Endothelial cells and astrocytes were immunostained with antibodies
cells and astrocytes were immunostained with both H-300 and Z0334. The cells
ured cells were also reacted with anti-GM1 or GMR6 with (insets) or without
trocytes, respectively. Arrowheads indicate the process of astrocyte. Bars, 50 μm.
Fig. 9. Assembly of hereditary variant types of Aβ in the presence of various
gangliosides. ThT fluorescence intensities of Aβ solutions incubated in the
presence of various gangliosides. The ThT fluorescence intensities of solutions
containing Aβ alone or liposomes alone were negligible (data not shown). Each
column indicates the average±SD of four values. *p<0.0001 versus the value of
the wild-type Aβ (one-way ANOVA combined with Sheffe's test). (From
Yamamoto et al., FEBS Lett 579: 2185–2190, 2005).
1950 K. Yanagisawa / Biochimica et Biophysica Acta 1768 (2007) 1943–1951cerebrovascular smooth muscle (HCSM) cells, which are a
preferable site for the deposition of these Aβs, were
subjected to thin-layer chromatography to determine the
gangliosides that are expressed by these cells. Notably,
HCSM cells exclusively express GM3 [28] (Fig. 8a). In
contrast, GD3 was preferentially expressed by astrocytes that
were in direct contact with endothelial cells [28] (Fig. 8b).
Taken together with the finding that the assembly of Dutch-
and Flemish-type Aβs is accelerated in the presence of GM3
and GD3, respectively [28] (Fig. 9), these results suggest that
the region-specific assembly and deposition of Aβ depend
on local gangliosides in the brain. In contrast to the
expression of GM3 and GD3, which are likely responsible
for the region-specific deposition of particular Aβ species,
GM1 is rather broadly expressed in the brain, at least,
apparently beyond the preferential site of Aβ deposition. As
aforementioned, GM1 content in membrane microdomains of
neuronal membranes can be altered under certain biological
conditions such as aging and the expression of apoE4. Thus,
it will be critically important to elucidate whether GM1
expression changes in a region-specific manner in the brain
before AD development.
8. Conclusion
Previous studies suggest that the expression of gangliosides
is an environmental factor that induces the assembly and
deposition of Aβ in the brain. A challenge for future studies is
to elucidate the mechanism underlying GAβ generation in the
brain, which may provide new insights into the pathophysiol-
ogy of AD. Moreover, on the basis of the finding that the
conformation of GAβ is distinct from those of soluble Aβs and
Aβs assembled into amyloid fibrils, it may be possible to
develop a novel therapeutic strategy that specifically targets
GAβ as a seed for Aβ assembly.Acknowledgments
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